Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial. This is an ASCO Meeting Abstract from the 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results